The Evolving Business of Science
New communication media (internet, cellular phones, etc.) have enabled changes and improvements in the R&D process. Not surprisingly, the first wave of innovations are those focused on improving operations and productivity of this enormously complex endeavor. However, the future potential exists for transforming the roles and organizational structures of the businesses and scientists. What might those transformations be? How soon can we expect them? And, what should we do, now, to be prepared? We’ll explore these questions, and hopefully challenge our imagination to find creative ways of adding value — and not just by “electronifying” the traditional processes.
Alpheus Bingham, Ph.D. President and Chief Executive Officer, Innocentive, Inc., and Vice President, e.Lilly, Eli Lilly and Company.
Dr. Bingham has been a strong advocate of open innovation and co-founded InnoCentive, Inc., along with other ventures that create the advantages of open and networked organizational structures. He has lectured extensively at both national and international events. He is a Visiting Scholar at the National Center for Supercomputing Application at the University of Illinois at Champaign-Urbana. He is also the former chairman of the Board of Editors of the Research Technology Management Journal.
He currently serves on the Board of Directors of RelayHealth Corporation, Fast Track Systems, Inc., and Collaborative Drug Discovery, Inc., and the advisory boards of Phase Forward, Inc., YourEncore, Inc. and Coalesix, Inc.
He has over 25 years of experience in pharmaceutical research and development, research collaborations, portfolio management and R&D strategic planning. During his career he was instrumental in creating and developing Eli Lilly's portfolio management process as well as establishing the divisions of Research Acquisitions, the Office of Alliance Management and e.Lilly, a unit for business innovation from which various business entities were co-founded, including InnoCentive, Inc., YourEncore, Inc., Coalesix, Inc., Maaguzi, Inc., Seriosity and Colaborative Drug Discovery, Inc.
Dr. Bingham has been with Eli Lilly since 1978 where he has served in various capacities, including head of Pharmaceutical Research, Director of Formulations Research and Development, Director of Medical Planning and Strategy and Managing Director of the Lilly Development Centre in Belgium. In addition, Dr. Bingham has served as Executive Director of Pharmaceutical Projects Management, Vice President of Sourcing Innovation/Portfolio Management and Vice President of Research and Development Strategy.
Dr. Bingham received a B.S. in chemistry from Brigham Young University and a Ph.D. in organic chemistry from Stanford University.
Our work is centered around a series of Focus Areas that we believe are the future of science and technology.
We’re continually developing new technologies, many of which are available for Commercialization.